Valneva’s chikungunya virus vaccine granted breakthrough designation

French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA). The chikungunya vaccine – VLA1553 – has also previously been awarded an FDA fast track designation and a European Medicines Agency (EMA) PRIME designation, in December 2018 and October 2020 respectively. Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus. Although the mortality with chikungunya virus is low, morbidity is high, with clinical symptoms including acute onset of fever, debilitating joint and muscle pain, headache, rash, nausea and chronic arthralgia.

For further information, see PharmaTimes (http://www.pharmatimes.com/news/valnevas_chikungunya_vaccine_granted_breakthrough_designation_1372915)

Leave a Reply

Your email address will not be published. Required fields are marked *